Evidence map›Paper›PMID 27923045›Full record

ArticlePLoS medicine2016

Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases.

Katherine A Hoadley, Marni B Siegel, Krishna L Kanchi, Christopher A Miller, Li Ding, Wei Zhao, Xiaping He, Joel S Parker, Michael C Wendl, Robert S Fulton and 5 more

Erratum issuedOpen access · goldAbstract readCase Reports
In one paragraph

Article in PLoS medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 107 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Breast cancers as ecosystems: a metabolic perspective.Cellular and molecular life sciences : CMLS · 2023
    Review
  16. Article
  17. Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  18. Article
  19. Beyond Genetics: Metastasis as an Adaptive Response in Breast Cancer.International journal of molecular sciences · 2022
    Review
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Katherine A HoadleyDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Marni B SiegelDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Krishna L KanchiMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri, United States of America.
Christopher A MillerMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri, United States of America.ORCID http://orcid.org/0000-0003-4266-6700
Li DingMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri, United States of America.
Wei ZhaoDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Xiaping HeLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Joel S ParkerDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID http://orcid.org/0000-0003-2080-6901
Michael C WendlMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri, United States of America.ORCID http://orcid.org/0000-0002-5694-2668
Robert S FultonMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri, United States of America.
Ryan T DemeterMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri, United States of America.
Richard K WilsonMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri, United States of America.ORCID http://orcid.org/0000-0002-1992-1358
Lisa A CareyDivision of Hematology-Oncology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Charles M PerouDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID http://orcid.org/0000-0001-9827-2247
Elaine R MardisMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri, United States of America.
James S. McDonnell Foundation · USUniversity of North Carolina at Chapel Hill · US

Funding

Large Scale Genome SequencingU54HG003079 · NHGRI · WASHINGTON UNIVERSITY · PI DUTCHER, SUSAN K · 2004 to 2016
$445.7M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KATHERINE A. HOADLEY · 1992 to 2026
$59.3M
Zonisamide in Patients with Neuropathic Pain Associated with Diabetic NeuropathyM01RR000046 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOY, MELANIE S · 1985 to 2008
$38.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
Therapeutic Targeting of Breast Cancer Tumor Initiating CellsR01CA148761 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, ROSEN, JEFFREY MARK · 2010 to 2025
$6.5M
Deep Discovery and Clinical Interpretation of Germline and Somatic Cancer DriversU24CA211006 · NCI · WASHINGTON UNIVERSITY · PI DING, LI, GOVINDAN, RAMASWAMY · 2016 to 2020
$1.8M
Mouse Models of Metastatic Triple-Negative Breast Cancer for Therapeutic TestingR01CA195754 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, ROSEN, JEFFREY MARK · 2015 to 2017
$1.7M
Establishing Genetic Drivers of Breast Cancer MetastasesF30CA200345 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SIEGEL, MARNI B · 2015 to 2018
$151k
NCI NIH HHS F30 CA200345NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA058223NCI NIH HHS R01 CA148761NCI NIH HHS R01 CA195754NCI NIH HHS U24 CA211006NCRR NIH HHS M01 RR000046NHGRI NIH HHS U54 HG003079NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

backgroundMetastasis is the main cause of cancer patient deaths and remains a poorly characterized process. It is still unclear when in tumor progression the ability to metastasize arises and whether this ability is inherent to the primary tumor or is acquired well after primary tumor formation. Next-generation sequencing and analytical methods to define clonal heterogeneity provide a means for identifying genetic events and the temporal relationships between these events in the primary and metastatic tumors within an individual. METHODS AND

findingsWe performed DNA whole genome and mRNA sequencing on two primary tumors, each with either four or five distinct tissue site-specific metastases, from two individuals with triple-negative/basal-like breast cancers. As evidenced by their case histories, each patient had an aggressive disease course with abbreviated survival. In each patient, the overall gene expression signatures, DNA copy number patterns, and somatic mutation patterns were highly similar across each primary tumor and its associated metastases. Almost every mutation found in the primary was found in a metastasis (for the two patients, 52/54 and 75/75). Many of these mutations were found in every tumor (11/54 and 65/75, respectively). In addition, each metastasis had fewer metastatic-specific events and shared at least 50% of its somatic mutation repertoire with the primary tumor, and all samples from each patient grouped together by gene expression clustering analysis. TP53 was the only mutated gene in common between both patients and was present in every tumor in this study. Strikingly, each metastasis resulted from multiclonal seeding instead of from a single cell of origin, and few of the new mutations, present only in the metastases, were expressed in mRNAs. Because of the clinical differences between these two patients and the small sample size of our study, the generalizability of these findings will need to be further examined in larger cohorts of patients.

conclusionsOur findings suggest that multiclonal seeding may be common amongst basal-like breast cancers. In these two patients, mutations and DNA copy number changes in the primary tumors appear to have had a biologic impact on metastatic potential, whereas mutations arising in the metastases were much more likely to be passengers.

Indexed as

Disease ProgressionAgedBreast NeoplasmsFemaleGenomicsHumansMiddle AgedMutationNeoplasms, Basal CellRetrospective Studies

Identifiers

PMID27923045
PMCPMC5140046
OpenAlexW2560102897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.